文献速递泌尿生殖腹部MR

PI-RADS升级规则:对前列腺癌检出及MRI导向诊断路径中活检避免的影响

PI-RADS Upgrading Rules: Impact on Prostate Cancer Detection and Biopsy Avoidance of MRI-Directed Diagnostic Pathways.
PubMed 文献 · AJR Am J Roentgenol · 2024-05-15

该回顾性分析纳入716例接受前列腺MRI后活检的患者,比较应用与不应用PI-RADS升级规则时临床显著前列腺癌检出和活检避免情况。结果显示,按指南应用升级规则的风险导向路径在7.5%~30.0%概率阈值下净获益最高,不应用升级规则会降低该路径的净临床获益。

要点

  • 按指南应用PI-RADS升级规则的风险导向路径净获益最高。
  • 不应用升级规则时,MRI聚焦路径每漏诊1例csPCa避免5.5次活检。
  • 不应用升级规则时,风险导向路径每漏诊1例csPCa避免1.9次活检。

核心结论

  • 不应用PI-RADS升级规则会降低风险导向MRI诊断路径的净临床获益(权衡csPCa检出与活检避免),支持应用升级规则优化活检选择。

研究设计与样本

  • 回顾性分析前瞻性维护的临床登记数据,纳入2016年1月至2020年5月无已知前列腺癌、接受前列腺MRI后活检的患者716例,以ISUP分级组≥2为临床显著前列腺癌(csPCa)标准。

关键影像表现/征象

  • 移行区PI-RADS 3分主导病灶与升级病灶的csPCa频率分别为20%与19%,无显著差异(p > .05)。
  • 移行区PI-RADS 4分主导病灶与升级病灶的csPCa频率分别为33%与26%,无显著差异(p > .05)。
  • 外周带PI-RADS 4分主导病灶与升级病灶的csPCa频率分别为58%与45%,无显著差异(p > .05)。

诊断标准与关键数值

  • csPCa定义为ISUP分级组≥2。
  • 活检全部路径的csPCa频率为53%、活检避免为0%。
  • 按指南MRI聚焦路径(PI-RADS ≤ 2不活检)的csPCa频率为52%、活检避免为13%。
  • 不应用升级规则MRI聚焦路径的csPCa频率为51%、活检避免为16%。
  • 按指南风险导向路径(PSA密度 ≥ 0.15 ng/mL2选择PI-RADS ≤ 3患者活检)的csPCa频率为52%、活检避免为19%。

临床应用与阅片要点

  • 在7.5%~30.0%的活检选择概率阈值范围内,按指南应用升级规则的风险导向路径净获益最高。
  • 不应用升级规则时,MRI聚焦路径每漏诊1例csPCa避免5.5次活检,风险导向路径每漏诊1例csPCa避免1.9次活检。
  • 本研究支持应用PI-RADS升级规则以优化活检选择,尤其在风险导向路径中。

局限性

  • 本文为回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. PI-RADS incorporates rules by which ancillary sequence findings upgrade a dominant score to a higher final category. Evidence on the upgrading rules' impact on diagnostic pathways remains scarce. OBJECTIVE. The purpose of this article was to evaluate the clinical net benefit of the PI-RADS upgrading rules in MRI-directed diagnostic pathways. METHODS. This study was a retrospective analysis of a prospectively maintained clinical registry. The study included patients without known prostate cancer who underwent prostate MRI followed by prostate biopsy from January 2016 to May 2020. Clinically significant prostate cancer (csPCa) was defined as International Society of Urological Pathology (ISUP) grade group 2 and higher. csPCa detection was compared between dominant (i.e., no upgrade rule applied) and upgraded lesions. Decision-curve analysis was used to compare the net benefit, considering the trade-off of csPCa detection and biopsy avoidance, of MRI-directed pathways in scenarios considering and disregarding PI-RADS upgrading rules. These included a biopsy-all pathway, MRI-focused pathway (no biopsy for PI-RADS ≤ 2), and risk-based pathway (use of PSA density ≥ 0.15 ng/mL2 to select patients with PI-RADS ≤ 3 for biopsy). RESULTS. The sample comprised 716 patients (mean age, 64.9 years; 93 with a PI-RADS ≤ 2 examination, 623 with total of 780 PI-RADS ≥ 3 lesions). Frequencies of csPCa were not significantly different between dominant and upgraded PI-RADS 3 transition zone lesions (20% vs 19%, respectively), dominant and upgraded PI-RADS 4 transition zone lesions (33% vs 26%), and dominant and upgraded PI-RADS 4 peripheral zone lesions (58% vs 45%) (p > .05). In the biopsy-all, per-guideline MRI-focused, MRI-focused disregarding upgrading rules, per-guideline risk-based, and risk-based disregarding upgrading rules pathways, csPCa frequency was 53%, 52%, 51%, 52%, and 48% and biopsy avoidance was 0%, 13%, 16%, 19%, and 25%, respectively. Disregarding upgrading rules yielded 5.5 and 1.9 biopsies avoided per missed csPCa for MRI-focused and risk-based pathways, respectively. At probability thresholds for biopsy selection of 7.5-30.0%, net benefit was highest for the per-guideline risk-based pathway. CONCLUSION. Disregarding PI-RADS upgrading rules reduced net clinical bene fit of the risk-based MRI-directed diagnostic pathway when considering trade-offs between csPCa detection and biopsy avoidance. CLINICAL IMPACT. This study supports the application of PI-RADS upgrading rules to optimize biopsy selection, particularly in risk-based pathways.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. de Oliveira Correia ET, Purysko AS, Paranhos BM, et al. PI-RADS Upgrading Rules: Impact on Prostate Cancer Detection and Biopsy Avoidance of MRI-Directed Diagnostic Pathways. AJR Am J Roentgenol. 2024. PMID: 38353450. doi:10.2214/AJR.23.30611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。